GET DAILY SIGNALSWhy Is Precision BioSciences (DTIL) Stock Up +17.49% Today?
Key Takeaways
- Shares of DTIL surged roughly 17.49%, climbing from a prior close of $8.12 to about $9.54 in intraday trading.
- The primary catalyst was the pricing of a $125 million underwritten stock offering that drew participation from prominent life-sciences investors.
- Supportive secondary drivers include fresh analyst reaffirmations and anticipation around an upcoming late-breaking data presentation for its lead gene-editing program.
- The move extends a multi-session rally and reflects broader optimism across clinical-stage gene-editing names.
- Traders are watching the AASLD Liver Meeting data abstract and the closing of the capital raise for the next directional cues.
- For more on Price Targets, Earnings, and Forecast data, explore these dedicated pages.
- To see how AI trading bots are positioning in names like this, visit Trending AI Robots.
Opening Summary
Precision BioSciences, Inc. (DTIL), a clinical-stage gene-editing company built around its proprietary ARCUS platform, saw its shares rally sharply on Wednesday. The stock climbed roughly 17.49% to about $9.54 in intraday trading, up from a prior-session close of $8.12. Markets attributed the advance primarily to the pricing of a $125 million underwritten offering that attracted several marquee healthcare investors, combined with renewed analyst support and pipeline momentum heading into a key medical conference.
Catalyst Breakdown
A Capital Raise That Signaled Confidence
The dominant driver behind the session's move was the company's announcement that it had priced a $125 million underwritten offering of common stock and pre-funded warrants. The deal, priced at $7.75 per share with participation from new and existing investors including First Light Asset Management, MPM BioImpact, Bleichroeder, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, and Driehaus Capital Management, is expected to close on or about November 6. While secondary offerings are often dilutive, the caliber of the participating institutions was read by the market as a strong vote of confidence in the company's pipeline, helping DTIL shares extend their gains despite the added share count.
Pipeline Momentum and Upcoming Data
Precision BioSciences has been building clinical momentum around its two lead programs, PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. A late-breaking oral presentation for the PBGENE-HBV ELIMINATE-B trial is scheduled for The Liver Meeting 2026, with the associated data abstract slated for release on November 5. The prospect of near-term efficacy data in a gene-editing setting added a speculative bid to the stock, reinforcing the earnings-driven and news-driven rally.
Analyst Support
Analyst commentary also contributed to the bullish tone. Coverage on DTIL carries a "Moderate Buy" consensus, and at least one firm reiterated a Buy rating during the session, underscoring a favorable longer-term view of the ARCUS platform's ability to deliver durable gene edits. The reiteration, coming alongside the financing news and the data-readout catalyst, helped sustain buying interest.
Market Context and Trading Activity
The advance did not occur in isolation. DTIL had already posted a double-digit percentage gain in the prior session, and Wednesday's move extended that momentum as investor attention turned to the financing and the upcoming conference data. Trading volume has been elevated relative to recent daily averages, reflecting genuine participation rather than a thin, low-liquidity drift. The rally also tracked strength across clinical-stage biotechnology and gene-editing peers, a segment that has been sensitive to positive clinical catalysts and strategic capital raises. The move carried the stock toward the upper end of its recent trading range, a technical signal that contributed additional momentum.
What Comes Next for DTIL
The immediate focus for DTIL is the release of the PBGENE-HBV data abstract and the subsequent oral presentation at The Liver Meeting 2026, which could validate or challenge the therapeutic promise underpinning the recent rally. Investors will also monitor the closing of the $125 million offering, which strengthens the company's balance sheet as it advances PBGENE-HBV and PBGENE-DMD through clinical development. Quarterly financial results remain a recurring checkpoint, and any delays in enrollment, data readouts, or regulatory interactions represent key risks. As with most clinical-stage biotechs, volatility can swing in either direction depending on the quality of forthcoming data and broader risk appetite in the sector.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Exploring the Trending AI Robots section can help investors see how automated strategies are positioning in real time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DTIL in +16.84% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DTIL advanced for three days, in 188 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DTIL as a result. In 64 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for DTIL just turned positive on October 19, 2026. Looking at past instances where DTIL's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
DTIL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DTIL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 49 cases where DTIL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
DTIL broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DTIL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.015) is normal, around the industry mean (2.904). P/E Ratio (-7.896) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (2.997) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. DTIL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DTIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology to produce custom, genome-editing enzymes for human health and biological research
Industry Biotechnology
Advertisement